DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hodgkin Lymphoma

Intervention: Avastin (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Jeremy Abramson, MD, Principal Investigator, Affiliation: Massachusetts General Hospital

Summary

The purpose of this research study is to determine the effectiveness and safety of Avastin when combined with standard chemotherapy for Hodgkin lymphoma. Avastin works differently than standard chemotherapy drugs. It is a type of protein called an antibody which binds to a substance called VEGF(Vascular Endothelial Growth Factor). VEGF stimulates the growth of the blood vessels that feed tumors and encourages tumor cell growth. VEGF is produced in excess by Hodgkin lymphoma cells, and is associated with a poorer outcome in patients with Hodgkin lymphoma. When the activity of VEGF is interrupted in multiple other cancer types, the blood vessels around the tumor cells die resulting in less nutrient delivery and death to the tumor. Blocking of VEGF has also been shown to improve delivery of chemotherapy to cancer cells, making standard chemotherapy work better. This trial uses Avastin in combination with standard chemotherapy with the goal of improving the cure rate over chemotherapy alone.

Clinical Details

Official title: Avastin (Bevacizumab) in Combination With ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine clinical activity and safety of bevacizumab when combined with ABVD for primary therapy of Hodgkin lymphoma

Secondary outcome: To evaluate effect of therapy on circulating angiogenic factors and correlate with tissue expression of VEGF and receptors.

Detailed description: Participants will be given Avastin as well as ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) intravenously on days 1 and 15 of a 28 day cycle. Participants will receive up to a total of 6 cycles of therapy.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18 years of age or older

- Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the

subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, and classical Hodgkin lymphoma unspecified

- Advanced stage (Stage III or IV) disease

- Measurable disease on cross sectional imaging

- ECOG Performance Status 0-2

- Adequate blood counts and organ function

Exclusion Criteria:

- Pregnant or lactating women

- Laboratory Parameters as outlined in the protocol

- LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan

- DLCO less than 60% as measured by pulmonary function tests

- Prior history of another malignancy (except for non-melanoma skin cancer or in situ

cervical or breast cancer) unless disease free for over one year

- Current or recent (within 4 weeks of the first infusion of this study) participation

in an experimental drug study

- Life expectancy of less than 12 weeks

- Inability to comply with study procedures

- Inability to give informed consent

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study

enrollment

- History of stroke or transient ischemic attack within 6 months prior to study

enrollment

- Known CNS involvement of Hodgkin lymphoma

- Significant vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diatheses or coagulopathy

- Use of daily anticoagulant medications including warfarin, heparins, or aspirin

>325mg daily

- Major surgical procedure or significant traumatic injury within 28 days prior to

study enrollment or anticipation of need for major surgical procedure during the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular

access device, within 7 days of study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal

abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening

- Known hypersensitivity to any component of bevacizumab

- Pregnant or lactating

Locations and Contacts

Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information

Starting date: September 2008
Last updated: April 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017